《EAU男性性腺功能低下指南(2012年版)》解读(3)
 |
| 第1页 |
参见附件。
[6]Haider A， Gooren LJ， Padungton P， et al. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes， 2010，118(3)：167-171.
[7]Giltay EJ， Tishova YA， Mskhalaya GJ， et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in men with metabolic syndrome. J Sex Med，2010，7(7)：2572-2582
[8]Bassil N， Alkaade S， Morley JE. The benefits and risks of testosterone replacement therapy： a review. Ther Clin Risk Manag， 2009，5(3)：427-448.
[9]Zitzman M， Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscolar testosterone undecanoate therapy in hipogonadal men. J Clin Endocrinol Metab， 2007，92(10)：3844-3853.
[10]Medras M， Filus A， Jozkow P， et al. Breast cancer and long term hormonal treatment of male Hypogonadism. Breast Cancer Res Treat， 2006，96(3)：263-265.
[11]Saad F， Aversa A， Isidori AM， et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol， 2011，165(5)：675-685.
[12]Fernández-Balsells MM， Murad MH， Lane M， et al. Adverse effects of testosterone therapy in adult men： a systematic review and meta-analysis. J Clin Endocrinol Metab Jun， 2010，95(6)：2560-2575.
您现在查看是摘要介绍页，详见PDF附件(3210kb)。